EyePoint (EYPT) Cash from Financing Activities (2011 - 2026)
EyePoint (EYPT) posted Cash from Financing Activities of -$2.6 million for Q1 2026, down 101.57% sequentially from $167.0 million in Q4 2025, and down 174.87% YoY from $3.5 million in Q1 2025.
Analysis
EyePoint (EYPT) Cash from Financing Activities (2011 - 2026) Analysis & Trends
EyePoint has reported Cash from Financing Activities for 16 years, with the latest figure at -$2.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 174.87% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.0 million (up 5.54% YoY) and the FY2025 annual result came in at $173.6 million, up 5.87% from the prior year.
- Cash from Financing Activities fell to -$2.6 million in Q1 2026 per EYPT's latest filing, from $167.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $218.5 million in Q4 2023 and troughed at -$36.7 million in Q2 2023.
- A 5-year average of $30.7 million and a median of $115000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 376798.28% in 2023, down 13181.88% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$58000.0 in 2022, then surged by 376798.28% to $218.5 million in 2023, then tumbled by 30.57% to $151.7 million in 2024, then increased by 10.07% to $167.0 million in 2025, then plunged by 101.57% to -$2.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.6 million, $167.0 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 19.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.99 Mn |
| Mar 31, 2026 | -2.61 Mn |
| Dec 31, 2025 | 166.96 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | -951,000.00 |
| Dec 31, 2024 | 151.69 Mn |
| Sep 30, 2024 | 11.89 Mn |
| Jun 30, 2024 | 329,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | 218.49 Mn |
| Sep 30, 2023 | 10.36 Mn |
| Jun 30, 2023 | -36.66 Mn |
| Mar 31, 2023 | -5.12 Mn |
| Dec 31, 2022 | -58,000.00 |
| Sep 30, 2022 | 92,000.00 |
| Jun 30, 2022 | -276,000.00 |
| Mar 31, 2022 | -448,000.00 |
| Dec 31, 2021 | 108.52 Mn |
| Sep 30, 2021 | -2,000.00 |